Molecular docking studies have become an essential tool in the field of drug discovery, particularly for identifying potential inhibitors of AChE, an enzyme critically involved in the pathophysiology of Alzheimer’s disease. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.